Diabetes Research and Clinical Practice
Volume 74, Issue 2, Supplement , Pages S34-S40 , 30 November 2006

Inflammatory markers as risk factors for microangiopathy in type 1 diabetic patients on functional intensive insulin therapy from the onset of the disease

References 

  1. DCCT Trial Research Group. The effect of Intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977–986
  2. EDIC Research Group. Epidemiology of diabetes interventions and complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the diabetes control and complications trial cohort. Diab. Care. 1999;22:99–111
  3. Berger M, Műhlhauser I. Implementation of intensified insulin therapy: a European perspective. Diabet. Med. 1995;12:201–208
  4. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ. 2002;325:746–749
  5. Műller UA, Femerling M, Reinauer KM, Risse A, Voss M, Jorgens V, et al. Intensified treatment and education of type 1 diabetes as clinical routine. Diab. Care. 1999;22(Suppl. 2):B29–B34
  6. Lawson ML, Gerstein HC, Tsui E, Zinman B. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. Diab. Care. 1999;22(Suppl. 2):B35–B39
  7. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, et al. CD vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes, the EURODIAB prospective complications study. Diab. Care. 2003;26:2165–2173
  8. Schram MT, Chatuverdi N, Schalkwijk CG, Fuller JH, Stehouwer CDA. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB prospective complications study. Diabetologia. 2005;48:370–378
  9. Bradley C. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Chur, Switzerland: Harwood Academic Publishers; 1994;
  10. Krolewski AS, Warram JH, Christlieb AL, Busick EJ, Kahn CR. The changing natural history of nephropathy in type 1 diabetes. Am. J. Med. 1985;78:785–794
  11. Donaghue KC, Craig ME, Chan AK, Fairchild JM, Cusumano JM. Prevalence of diabetes complications 6 years after diagnosis in an incident of childhood diabetes. Diabet. Med. 2005;22:711–718
  12. Stephenson JM, Fuller JH. Microalbuminuria is not rare before 5 years of IDDM. EURODIAB IDDM complications study group and the WHO multinational study of vascular disease in diabetes study group. J. Diab. Compl. 1994;8:166–173
  13. Porta M, Sjoelie AK, Chaturvedi N, Stevens L, Rottiers R, Veglio M, et al. Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB prospective complications study. Diabetologia. 2001;44:2203–2209
  14. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control?. J. Diab. Compl. 2005;19:178–181
  15. Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti G. Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet. 1993;342:883–887
  16. Ekstrand AV, Groop PH, Grönhagen-Riska C. Insulin resistance precedes microalbuminuria in patients with insulin-dependent diabetes mellitus. Nephrol. Dial. Transplant. 1998;13:3079–3083
  17. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers R, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. The EURODIAB prospective complications study. Kidney Int. 2001;60:219–227
  18. Schlöndorff D. Cellular mechanisms of lipid injury in the glomerulus. Am. J. Kidney Dis. 1993;22:279–285
  19. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105:1801–1815
  20. The EUCLID Study GroupChaturvedi N, Sjoelie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet. 1998;351:28–31
  21. The Microalbuminuria Collaborative Study Group. Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven-year prospective study. Diabet. Med. 1999;16:918–925
  22. Schmidt AM, Stern DM. Hyperinsulinemia and vascular dysfunction. The role of nuclear factor κB, yet again. Circ. Res. 2000;87:722–724
  23. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J. Clin. Invest. 2005;115:1111–1119
  24. Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, et al. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation. 2005;111:2446–2453
  25. de Winther MP, Kanters E, Kraal G, Hofker MH. Nuclear factor κB signaling in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2005;25:904–914
  26. Ross R. Atherosclerosis—an inflammatory disease. N. Engl. J. Med. 1999;340:115–126
  27. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143
  28. Lopes-Virella MF, Virella G. Immune mechanism of atherosclerosis in diabetes mellitus. Diabetes. 1992;41(Suppl. 2):86–91

PII: S0168-8227(06)00277-4

doi: 10.1016/j.diabres.2006.06.012

Diabetes Research and Clinical Practice
Volume 74, Issue 2, Supplement , Pages S34-S40 , 30 November 2006

Article Tools